TY - JOUR
T1 - Synchronized expressions of serum osteopontin and B cell–activating factor in autoimmune thyroid disease
AU - Cheng, Chao-Wen
AU - Tang, Kam-Tsun
AU - Fang, Wen-Fang
AU - Lin, Jiunn-Diann
N1 - Funding Information:
We thank all of the participants in this study. This work was supported by a grant from Taipei Medical University and Shuang‐Ho Hospital (107TMU‐SHH‐12).
Publisher Copyright:
© 2019 Stichting European Society for Clinical Investigation Journal Foundation
PY - 2019/7
Y1 - 2019/7
N2 - Background: Osteopontin (OPN) is recognized as a potent immunoregulator of autoimmune disease. In the study, we tried to explore the association of serum OPN levels with autoimmune thyroid disease, including Graves' disease (GD) and Hashimoto's thyroiditis (HT), in an ethnic Chinese population. Materials and methods: We enrolled 131 patients with GD, 33 patients with HT and 123 healthy controls. Serum OPN, B cell–activating factor (BAFF) and interferon (IFN)-α levels were quantified. Graves' disease patients with high thyroid function at the time of sample collection were defined as having active GD, while the other patients were defined as having inactive GD. Results: Serum OPN levels were higher in active GD than in inactive GD and the control groups (P = 0.001 and P = 0.018, respectively). In GD, significant associations of OPN levels with thyroid-stimulating hormone receptor antibody (TSHRAb) levels were observed in women (r = −0.344, P = 0.002, and r = 0.440, P = 0.004, respectively) but not in men. Osteopontin levels were associated with BAFF levels only in women with GD or HT (r = 0.506, P < 0.001 and r = 0.430, P = 0.025, respectively), but not in men with GD or HT. Conclusions: Serum OPN levels were upregulated in active GD, and serum OPN levels were associated with thyroid function and TSHRAb levels in GD. Additionally, OPN levels were correlated with BAFF levels in GD and HT. The associations of OPN levels with clinical phenotypes of GD and BAFF levels showed a dimorphic pattern.
AB - Background: Osteopontin (OPN) is recognized as a potent immunoregulator of autoimmune disease. In the study, we tried to explore the association of serum OPN levels with autoimmune thyroid disease, including Graves' disease (GD) and Hashimoto's thyroiditis (HT), in an ethnic Chinese population. Materials and methods: We enrolled 131 patients with GD, 33 patients with HT and 123 healthy controls. Serum OPN, B cell–activating factor (BAFF) and interferon (IFN)-α levels were quantified. Graves' disease patients with high thyroid function at the time of sample collection were defined as having active GD, while the other patients were defined as having inactive GD. Results: Serum OPN levels were higher in active GD than in inactive GD and the control groups (P = 0.001 and P = 0.018, respectively). In GD, significant associations of OPN levels with thyroid-stimulating hormone receptor antibody (TSHRAb) levels were observed in women (r = −0.344, P = 0.002, and r = 0.440, P = 0.004, respectively) but not in men. Osteopontin levels were associated with BAFF levels only in women with GD or HT (r = 0.506, P < 0.001 and r = 0.430, P = 0.025, respectively), but not in men with GD or HT. Conclusions: Serum OPN levels were upregulated in active GD, and serum OPN levels were associated with thyroid function and TSHRAb levels in GD. Additionally, OPN levels were correlated with BAFF levels in GD and HT. The associations of OPN levels with clinical phenotypes of GD and BAFF levels showed a dimorphic pattern.
KW - B cell–activating factor
KW - Graves' disease
KW - Hashimoto's thyroiditis
KW - autoimmune thyroid disease
KW - osteopontin
KW - Thyroxine/metabolism
KW - B-Cell Activating Factor/metabolism
KW - Up-Regulation/physiology
KW - Humans
KW - Male
KW - Sex Characteristics
KW - Thyrotropin/metabolism
KW - Case-Control Studies
KW - Osteopontin/metabolism
KW - Graves Disease/blood
KW - Adult
KW - Female
KW - Hashimoto Disease/blood
KW - Interferon-alpha/metabolism
KW - Thyroid Gland/immunology
KW - Autoantibodies/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85065712377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065712377&partnerID=8YFLogxK
U2 - 10.1111/eci.13122
DO - 10.1111/eci.13122
M3 - Article
C2 - 31034586
SN - 0014-2972
VL - 49
SP - e13122
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
IS - 7
M1 - e13122
ER -